FDAnews Drug Daily Bulletin
Pharmaceuticals / Commercial Operations

Teva Will Give California $69 Million to Put Pay-for-Delay Claims to Rest

Aug. 1, 2019

Israeli drug titan Teva Pharmaceuticals and two other drugmakers have agreed to settlements in California in order to shake allegations of anticompetitive pay-for-delay deals.

Teva was hit the hardest and will fork over $69 million to the state in order to quiet claims that it used pay-for-delay agreements to stall a generic narcolepsy drug, Provigil, from market for nearly six years.

According to the state’s attorney general, Xavier Becerra, Teva used four pay-for-delay agreements to illegally control sales of the drug between 2006 and 2012 and drove up the cost of the drug.

View today's stories